United Hospital Center (UHC) Urology is excited to announce that it will begin offering JELMYTO® (mitomycin) for pyelocalyceal solution, the first and only U.S. Food and Drug Administration (FDA)- approved treatment for adult patients with low-grade upper tract urothelial cancer (LG-UTUC).1 UHC is one of the centers in the U.S. that currently offers this innovative treatment option.
JELMYTO consists of mitomycin, an established chemotherapy, and sterile hydrogel, using UroGen’s proprietary sustained release RTGel™ technology. It was designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors, sparing the kidney. Unlike systemic chemotherapy that goes everywhere in the body, JELMYTO is delivered to the affected kidney region where the tumors are located. The sustained exposure of mitomycin for 4 to 6 hours makes chemoablation of low-grade tumors possible. JELMYTO is then excreted via normal urinary flow.1
Urothelial cancer is the tenth most commonly diagnosed cancer worldwide, with approximately 573,000 new cases. 2 Given many people with this type of cancer are generally older and have other co-morbidities, there is a significant unmet need for a less invasive treatment option, particularly one that spares the kidney. 3
“At UHC Urology, patients have access to a wide array of innovative tools, technologies, and techniques specifically designed to treat complex urinary diseases, such as UTUC,” said Grant L. Franklin, Jr., MD. “We look forward to offering JELMYTO as the latest advancement in the treatment of LG-UTUC.”
To learn more, call 681-342-3600.
- United States Jelmyto Prescribing Information. Available here: https://www.urogen.com/download/pdf/jelmyto_prescribing.pdf
- Sung et al. “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.” CA: A Cancer Journal for Clinicians. 2021 Feb 4. https://doi.org/10.3322/caac.21660.
- Fiuk and Schwartz. “Upper tract urothelial carcinoma: Paradigm shift towards nephron sparing management.” World J Nephrol. 2016 Mar 6; 5(2): 158–165. doi: 10 .5527/wjn.v5.i2.158.
Please note, the information provided throughout this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and video, on or available through this website is for general information purposes only. If you are experiencing related symptoms, please visit your doctor or call 9-1-1 in an emergency.